<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Middle East J Dig Dis</journal-id><journal-id journal-id-type="iso-abbrev">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">MEJDD</journal-id><journal-title-group><journal-title>Middle East Journal of Digestive Diseases</journal-title></journal-title-group><issn pub-type="ppub">2008-5230</issn><issn pub-type="epub">2008-5249</issn><issn-l>2008-5230</issn-l><publisher><publisher-name>Iranian Association of Gastroerterology and Hepatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28638586</article-id><article-id pub-id-type="pmc">5471100</article-id><article-id pub-id-type="doi">10.15171/mejdd.2017.58</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>
Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for <italic>Helicobacter Pylori</italic> Infection Eradication
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mansour-Ghanaei</surname><given-names>Fariborz</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pedarpour</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shafaghi</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="A03">
<sup>3</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Joukar</surname><given-names>Farahnaz</given-names></name><xref ref-type="aff" rid="A04">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup>Professor, Gastrointestinal &#x00026; Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
</aff><aff id="A02"><sup>2</sup>Researcher, GI Cancers Screening and Prevention Research Center (GCSPRC), Guilan University of Medical Sciences, Rasht, Iran
</aff><aff id="A03"><sup>3</sup>Associate Professor, GI Cancers Screening and Prevention Research Center (GCSPRC), Guilan University of Medical Sciences, Rasht, Iran
</aff><aff id="A04"><sup>4</sup>PhD by Research student, Faculty member, Gastrointestinal &#x00026; Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
</aff><author-notes><corresp id="COR1"><label>*</label><bold>Corresponding Author:</bold> Afshin Shafaghi, MD Associate Professor, GI Cancers Screening and Prevention Research Center (GCSPRC), Guilan University of Medical Sciences, Razi Hospital, Sardar-Jangle Ave., P.O. Box: 41448-95655, Rasht, Iran Tel: + 98 131 5535116 Fax: + 98 131 5534951 <email>drafshinshafaghi@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2017</year></pub-date><volume>9</volume><issue>2</issue><fpage>100</fpage><lpage>106</lpage><history><date date-type="received"><day>05</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>06</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by Middle East Journal of Digestive Diseases</copyright-statement><copyright-year>2017</copyright-year><license><license-p>
This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>). Non-commercial uses of the work are permitted, provided the original work is properly cited.
</license-p></license></permissions><self-uri xlink:href="http://www.mejdd.org">http://www.mejdd.org</self-uri><abstract><p>BACKGROUND </p><p>
<italic>Helicobacter pylori (H. pylori)</italic> infection is a major casual factor in any peptic diseases. Clarithromycin
as one of the drugs recommended for the infection eradication regimen has shown different
levels of resistance. The present study is comparing the effectiveness of clarithromycin- and
gemifloxacin - based quadruple regimens in <italic>H. pylori</italic> eradication.
</p><p>METHODS </p><p>
This was a prospective double blind randomized clinical trial on patients with clear indication
of <italic>H. pylori</italic> eradication. The patients were randomly divided into two groups: "BPAC group" treated with bismuth subcitrate (240 mg), pantoprazole (20 mg), amoxicillin (1 gr), and clarithromycin (500 mg), all twice daily, and the "BPAG group" treated with bismuth subcitrate, pantoprazole, and amoxicillin with same doses as "BPAC group" and gemifloxacin (320 mg daily) all for 10 days. Three months after the end of therapy, 14C-Urea breath test was performed to confirm the eradication.
All the patients were assessed for compliance and drug side effects. Based on per-protocol (PP)
and intention-to-treat (ITT) methods, data were analyzed and a P value&#x0003c;0.05 was considered as statistically
significant. This project has been registered in the Iranian registry of clinical trials (IRCT).
</p><p>RESULTS</p><p>
Three patients were excluded from the survey and finally, 179 patients (89 patients in BPAC
group and 90 patients in BPAG group) including 71(39.66%) men with the mean age of 46.4&#x000b1;12.3
years completed the treatment period. The incidence of side effects between the two study groups
did not differ significantly. The success rate of BPAC regimen eradication was remarkably greater
than BPAG regimen (ITT analysis; 89% vs 77%, respectively; CI 95%: 1.072-5.507, <italic>P</italic>&#x0003c;0.015 and
PP analysis; 91% vs 77.8% respectively; CI 95%: <italic>P</italic>&#x0003c;0.015). There was no significant relationship
between the demographic features and the eradication results.
</p><p>CONCLUSION</p><p>
The results showed that gemifloxacin is not a good alternative for clarithromycin in <italic>H. pylori</italic>
eradication regimens in our region.
</p></abstract><kwd-group><kwd><italic>Helicobacter pylori</italic> infection
</kwd><kwd>Eradication regimens</kwd><kwd>Clarithromycin</kwd><kwd>Gemifloxacin</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="30"/><page-count count="7"/></counts></article-meta><notes><p>Please cite this paper as:</p><p>
Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East J Dig Dis 2017;9:100-106. DOI: 10.15171/mejdd.2017.58.
</p></notes></front><body><sec sec-type="introduction" id="s1"><title>INTRODUCTION</title><p>
On the basis of the fact that there is a wide range of <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) infection prevalence rate among the world&#x02019;s populations (50-70%)<sup><xref rid="R1" ref-type="bibr">1</xref></sup> , it seems that it is the most common human infection worldwide. Also, some epidemiological surveys have reported that the infection has affected about 20-50% of the population in Western countries and up to 80% in developing countries.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup>
</p><p>
Currently, the strong relationship between <italic>H. pylori</italic> infection and chronic gastritis, peptic ulcer disease, and gastric cancers is well demonstrated.<sup><xref rid="R2" ref-type="bibr">2</xref>-<xref rid="R4" ref-type="bibr">4</xref></sup> On the other hand, eradication of the infection is associated with ulcer healing<sup><xref rid="R4" ref-type="bibr">4</xref></sup>, regression of mucosa associated tissue lymphoma<sup><xref rid="R5" ref-type="bibr">5</xref></sup>, and decreased cancer risk.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Therefore, the eradication of the pathogen is of great importance to reduce <italic>H.pylori</italic> related complications.
</p><p>
The most approved <italic>H. pylori</italic> infection eradication regimen, with a success rate of around 80%<sup><xref rid="R7" ref-type="bibr">7</xref></sup>, is a quadruple combination of an acid suppressor (usually a proton pump inhibitor), and bismuth subcitrate with two antibiotics (amoxicillin, metronidazole, tetracycline, or clarithromycin).<sup><xref rid="R8" ref-type="bibr">8</xref></sup>
</p><p>
Currently, due to the high level of antimicrobial resistance, patients&#x02019; poor compliance, and drugs side effects, the treatment failure rate is increasing.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Considering this worldwide problem, there has been a search for an alternative drug that is effective, safe, easy to use, inexpensive, and with a low propensity to induce the development of resistant strains.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup>
</p><p>
One of the drugs that show such a high level of resistance is clarithromycin.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In a recent study, Camargo and colleagues<sup><xref rid="R10" ref-type="bibr">10</xref></sup>, reported 12% resistance for clarithromycin. Also, some Iranian surveys such as those performed by Farshad<sup><xref rid="R11" ref-type="bibr">11</xref></sup>, Abadi<sup><xref rid="R12" ref-type="bibr">12</xref></sup>, and their colleagues showed a resistance rate of 5-45.2% for this macrolid. Based on these findings and the fact that Iran is one of the developing countries with high prevalence of <italic>H. pylori</italic> infection (83.5%)<sup><xref rid="R13" ref-type="bibr">13</xref></sup>, the importance of <italic>H. pylori</italic> eradication and replacing clarithromycin with other antibiotics becomes more evident.
</p><p>
The present study is evaluating the <italic>H. pylori</italic> eradication rate of gemifloxacin in comparison with clarithromycin in quadruple regimen combined with bismuth subcitrate, pantoprazole, and amoxicillin.
</p></sec><sec sec-type="materials and methods" id="s2"><title>MATERIALS AND METHODS</title><p>
This was a prospective double blind randomized clinical trial, designed by Gastrointestinal and Liver Diseases Research Center of Guilan University of Medical Sciences, in Rasht the capital of Guilan province, northern Iran, from October 2013 to August 2014.
</p><p>
We included the consecutive patients (aged between 18 to 80 years) with dyspepsia and no history of previous <italic>H. pylori</italic> treatment, referred to internal medicine and gastroenterology clinics. If the presence of <italic>H. pylori</italic> infection was established and there was a clear indication for the eradication therapy, the patient would be enrolled to the study. <italic>H. pylori</italic> infection defined as positive 14C-Urea breath test (UBT) or positive pathology of the endoscopic biopsy samples. The samples were analyzed by a pathologist who was blind to the study protocol. Dyspepsia is a general term that refers to symptoms originating from the upper gastrointestinal tract. As such, it may encompass a variety of symptoms. Typically, the affected patients describe epigastric pain but may also complain of heartburn, nausea, vomiting, abdominal distention, heartburn, early satiety, and anorexia.<sup><xref rid="R14" ref-type="bibr">14</xref></sup>
</p><p>
Exclusion criteria: Pregnant and breast feeding women, and patients with gastric and esophageal malignancies or surgeries, pyloric stenosis, liver cirrhosis, opium addiction, consumption of cholestyramine, chronic renal failure, congestive heart failure, history of seizure and hematologic disorders were excluded from the study.
</p><p>
Study protocol: At the first step, the demographic features were recorded and then all the patients were randomly divided into two groups. Randomization was done using the simple randomization method. The two study groups were: &#x0201c;BPAC group&#x0201d; (n=91) treated with bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1 gr, and clarithromycin 500 mg, all twice a day and the &#x0201c;BPAG group&#x0201d; (n=91) treated with bismuth subcitrate, pantoprazole, and amoxicillin with the same dose as the first group and gemifloxacin 320 mg daily, all for 10 days.
</p><p>
12 weeks after the end of the treatment, 14C-UBT was performed to confirm the eradication. All the patients were assessed for compliance and side effects. The severity of any side effects was classified as &#x0201c;mild&#x0201d; with no limitation of the usual daily activities, &#x0201c;moderate&#x0201d; with mild limitation, and &#x0201c;severe&#x0201d; with impossible daily activities. Also, compliance was acceptable when over 80% of the total medications were taken. The patients with severe side effects and no good compliance were excluded from the study. This study was reviewed and approved by the Ethics Committee of Guilan University of Medical Science, and written informed consent was obtained from all the participants. Also, this project has been registered in the Iranian registry of clinical trials (IRCT registration number: IRCT201310221155N17).
</p><p>
<bold>Statistical analysis:</bold> All data were statistically analyzed using SPSS software for windows version 21.0 (SPSS Inc., Chicago, IL, USA). Using Chi-square test, the gender distribution and the efficacy and frequency of side effects were analyzed. Based on per-protocol (PP) and intention-to-treat (ITT) methods, the data were assessed and a <italic>P</italic> value&#x0003c;0.05 was considered as statistically significant.
</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>
Due to severe drug side effects, three patients were excluded from the survey; two patients in BPAC group (a man with severe diarrhea and a woman with severe nausea and vomiting) and one patient in BPAG group (a woman with severe nausea and no compliance). Finally, 179 patients (89 patients in BPAC group and 90 patients in BPAG group) including 71 (39.66%) men and 108 women (60.34%) with the mean age of 46.4&#x000b1;12.3 years completed the treatment period. <xref ref-type="table" rid="T1">Table 1</xref> shows the demographic characteristics of the patients in both study groups.
</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>
Comparison of demographic features between the two study groups
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Demographic features</bold>
</td><td rowspan="1" colspan="1">
<bold>BPAG (%)</bold>
<break/>
<bold>n=90</bold>
</td><td rowspan="1" colspan="1">
<bold>BPAC (%)</bold>
<break/>
<bold>n=89</bold>
</td><td rowspan="1" colspan="1">
<italic>P</italic>
<bold> value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="2" colspan="1">Gender</td><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">31 (34.45)</td><td rowspan="1" colspan="1">40 (56.3)</td><td rowspan="2" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">59 (65.55)</td><td rowspan="1" colspan="1">49 (2.05)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="4" colspan="1">Age group</td><td rowspan="1" colspan="1">20&#x0003e;</td><td rowspan="1" colspan="1">1 (1.1)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="4" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">20-39</td><td rowspan="1" colspan="1">32 (35.56)</td><td rowspan="1" colspan="1">31 (34.83)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">40-59</td><td rowspan="1" colspan="1">47 (52.23)</td><td rowspan="1" colspan="1">47 (52.81)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">60&#x0003c;</td><td rowspan="1" colspan="1">10 (11.11)</td><td rowspan="1" colspan="1">11 (12.36)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="2" colspan="1">Smoking</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">8 (8.88)</td><td rowspan="1" colspan="1">6 (6.74)</td><td rowspan="2" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">82 (91.12)</td><td rowspan="1" colspan="1">83 (93.26)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="2" colspan="1">NSAIDs usage</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">29 (32.22)</td><td rowspan="1" colspan="1">23 (25.84)</td><td rowspan="2" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">61 (67.78)</td><td rowspan="1" colspan="1">66 (74.16)</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Duration of </td><td rowspan="1" colspan="1">&#x0003c; 1 month</td><td rowspan="1" colspan="1">75 (83.33)</td><td rowspan="1" colspan="1">72 (80.9)</td><td rowspan="2" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Symptoms</td><td rowspan="1" colspan="1">&#x0003e; 1 month</td><td rowspan="1" colspan="1">15 (16.64)</td><td rowspan="1" colspan="1">17 (19.1)</td></tr></tbody></table><table-wrap-foot><fn><p>
BPAG: Bismuth subcitrate, Pantoprazole, Amoxicillin, Gemifloxacin; BPAC: Bismuth subcitrate, Pantoprazol, Amoxicillin, Clarythromycin; NSAIDs: Nonsteroidal Anti-Inflammatory Drugs; p- value&#x0003c;0.05 considered as statistically significant
</p></fn></table-wrap-foot></table-wrap><p>
The incidence of side effects between the two study groups did not differ significantly. The most frequent drug side effect was mild abdominal pain (15 cases in BPAC group vs 14 cases in BPAG group, <xref ref-type="table" rid="T2">table 2</xref>).
</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>
Drugs side effects
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="2" colspan="1">
<bold> Table 2 Drugs side effects</bold>
<bold>Drugs Side Effects</bold>
</td><td colspan="2" align="center" rowspan="1">
<bold>BAPG</bold>
<break/>
<bold>n=90 (%)</bold>
</td><td colspan="2" align="center" rowspan="1">
<bold>BAPC</bold>
<break/>
<bold>n=89 (%)</bold>
</td><td rowspan="2" colspan="1">
<bold>P value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Mild</bold>
</td><td rowspan="1" colspan="1">
<bold>Moderate</bold>
</td><td rowspan="1" colspan="1">
<bold>Mild</bold>
</td><td rowspan="1" colspan="1">
<bold>Moderate</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">3 (3.33)</td><td rowspan="1" colspan="1">9 (10)</td><td rowspan="1" colspan="1">4 (4.5)</td><td rowspan="1" colspan="1">3 (3.37)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">7 (7.77)</td><td rowspan="1" colspan="1">6 (6.67)</td><td rowspan="1" colspan="1">2 (2.25)</td><td rowspan="1" colspan="1">9 (10.11)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Vomiting</td><td rowspan="1" colspan="1">3 (3.33)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">1 (1.12)</td><td rowspan="1" colspan="1">3 (3.37)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Heartburn</td><td rowspan="1" colspan="1">10 (11.11)</td><td rowspan="1" colspan="1">3 (3.33)</td><td rowspan="1" colspan="1">9 (10.11)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Abdominal pain</td><td rowspan="1" colspan="1">8 (8.88)</td><td rowspan="1" colspan="1">7 (7.77)</td><td rowspan="1" colspan="1">9 (10.11)</td><td rowspan="1" colspan="1">5 (5.62)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Loss of appetite</td><td rowspan="1" colspan="1">4 (4.45)</td><td rowspan="1" colspan="1">3 (3.33)</td><td rowspan="1" colspan="1">4 (4.5)</td><td rowspan="1" colspan="1">1 (1.12)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Cramps</td><td rowspan="1" colspan="1">3 (3.33)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">2 (2.25)</td><td rowspan="1" colspan="1">3 (3.37)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">4 (4.45)</td><td rowspan="1" colspan="1">5 (5.56)</td><td rowspan="1" colspan="1">6 (6.75)</td><td rowspan="1" colspan="1">4 (4.5)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Dizziness</td><td rowspan="1" colspan="1">4 (4.45)</td><td rowspan="1" colspan="1">6 (6.67)</td><td rowspan="1" colspan="1">7 (7.86)</td><td rowspan="1" colspan="1">5 (5.62)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Back pain</td><td rowspan="1" colspan="1">2 (2.22)</td><td rowspan="1" colspan="1">2 (2.22)</td><td rowspan="1" colspan="1">4 (4.5)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">NS</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Dry mouth</td><td rowspan="1" colspan="1">5 (5.56)</td><td rowspan="1" colspan="1">6 (6.67)</td><td rowspan="1" colspan="1">7 (7.86)</td><td rowspan="1" colspan="1">3 (3.37)</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>
CLD, chronic liver disease: EHPVO, extrahepatic portal vein obstruction; ESRD, endstage renal disease; HTN, hypertension; SMA, superior mesenteric artery; IBD, inflammatory bowel disease, NASH, non-alcoholic steatohepatitis; TB, tuberculosis; VA, villous atrophy
</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="table" rid="T3">Table 3</xref> shows the success rate of the two regimens based on two analyses; PP and ITT. Both analyses nearly showed similar results. Based on ITT analysis, the eradication rate achieved by the BPAC regimen was remarkably greater than that obtained by BPAG regimen (89% vs 77%, respectively; CI 95%: 1.072-5.507, OR=2.43, <italic>p</italic>&#x0003c;0.015). Also, based on PP analysis, the eradication rate achieved by the BPAC regimen was remarkably greater than that obtained by BPAG regimen (91% vs 77.8%, respectively; CI 95%: 1.2-6.975, OR=2.89, <italic>p</italic> &#x0003c;0.015). There was no significant relationship between the demographic features and the eradication results.
</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>
<italic>H. pylori</italic> eradication rate based on two analysis method
</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="2" colspan="1">
</td><td colspan="3" align="center" rowspan="1">
<bold>PP Analysis</bold>
</td><td rowspan="1" colspan="1">
<bold>P value</bold>
</td><td colspan="3" align="center" rowspan="1">
<bold>ITT Analysis</bold>
</td><td rowspan="1" colspan="1">
<bold>P value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Eradicated </td><td rowspan="1" colspan="1">Not eradicated</td><td rowspan="1" colspan="1">Success rate</td><td rowspan="3" colspan="1">0.015</td><td rowspan="1" colspan="1">Eradicated </td><td rowspan="1" colspan="1">Not eradicated</td><td rowspan="1" colspan="1">Success rate</td><td rowspan="3" colspan="1">0.03</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">BPAC </td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">91 %</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">89%</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">BPAC </td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">77.8 %</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">77%</td></tr></tbody></table><table-wrap-foot><fn><p>
PP: Per Protocol; ITT: Intention to treat; BPAG: Bismuth subcitrate, Pantoprazole, Amoxicillin, Gemifloxacin; BPAC: Bismuth subcitrate, Pantoprazol, Amoxicillin, Clarythromycin; p-value&#x0003c;0.05 considered as statistically significant
</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>
Currently, the treatment failure of <italic>H. pylori</italic> infection is increasing worldwide and an ideal therapeutic regimen has not yet been identified.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> There are several theories for this medical limitation such as antibiotic resistance with changing the bacterial morphology as antibiotic exposure happens from spiral to coccoid appearance, patients&#x02019; poor compliance, high gastric acidity, high bacterial load, and cytochrome P450 2C19 (CYP2C19) polymorphism.<sup><xref rid="R15" ref-type="bibr">15</xref>-<xref rid="R17" ref-type="bibr">17</xref></sup>
</p><p>
There are several studies declared that clarithromycin is an strong macrolide for <italic>H.pylori</italic> eradication, but this antibiotic shows a high level of resistant and is expensive and unavailable for every patient especially in some developing countries.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> A possible cross resistance between clarithromycin and erythromycin, an antibiotic that has been widely prescribed for various infections in Iran for many years, may partially explain the unexpectedly high resistance rate of clarithromycin.<sup><xref rid="R18" ref-type="bibr">18</xref></sup>
</p><p>
Fluoroquinolone-containing regimens are of other measures with good results for <italic>H. pylori</italic> infection treatment. One of these antibiotics is gemifloxacin, which inhibits DNA-gyrase and topoisomerase. Gemifloxacin prevents the cellular replication of gram-positive and gram-negative bacteria.<sup><xref rid="R19" ref-type="bibr">19</xref></sup>
</p><p>
There are a handful of studies in the literature on gemifloxacin, which claimed that in comparison with clarithromycin, gemifloxacin showed a higher treatment success rate in different infections.<sup><xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R23" ref-type="bibr">23</xref></sup> Here we tried to compare the treatment results of two quadruple regimens based on clarithromycin and gemifloxacin in <italic>H.pylori</italic> infection eradication. <xref ref-type="fig" rid="F1">Figure 1</xref> shows a summary of this survey&#x02019;s method and results.
</p><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flow diagram of clarithromycin versus gemifloxacin therapy </p></caption><graphic xlink:href="mejdd-9-100-g001"/><statement><p>
BPAC: Bismuth subcitrate, pantoprazole, amoxicillin, clarithromycin; BPAG: Bismuth subcitrate, pantoprazole, amoxicillin, gemifloxacin; UBT: 14C-Urea breath test; ITT: Intention to treat; PP: Per Protocol
</p></statement></fig><p>
Our results presented a success rate of 77% for gemifloxacin with the ITT and 89% with clarithromycin, respectively. Clinical success in the PP was 77.8% with gemifloxacin and 91% with clarithromycin, respectively.
</p><p>
Since the eradication rate of <italic>H. pylori</italic> infection by BPAC regimen was higher than 80%, it can be considered as an effective regimen in eradicating the infection. But, on the other hand, the BPAG regimen failed to achieve the eradication rate of 80%, so it cannot be used as an effective regimen for the eradication of <italic>H. pylori</italic> infection in our geographic region.
</p><p>
Our findings were similar to some other surveys presented the high power of clarithromycin in <italic>H. pylori</italic> infection treatment.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> For example, Fakheri and colleagues<sup><xref rid="R18" ref-type="bibr">18</xref></sup>, reported an eradication rate of 84% by ITT analysis for clarithromycin in quadruple therapy regimen. On the other hand, in contrast to our findings, there are several surveys declared that gemifloxacin was an effective antibiotic for <italic>H. pylori</italic> eradication.<sup><xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R28" ref-type="bibr">28</xref></sup> In a randomized clinical trial, Masoodi and co-workers<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, presented that gemifloxacin containing regimen was at least as effective as clarithromycin regimen and this new treatment could be considered as an alternative for the patients who cannot tolerate clarithromycin. Also, Chang WL and colleagues<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, concluded that, comparing to fluoroquinolones, gemifloxacin had a more effective anti-bacterial activity on clinical types of <italic>H.pylori</italic>. In the present study the effect of clarithromycin was lower among the new cases without previous first-line treatment while in our last study<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, the patients were resistant to clarithromycin. In contrast to our results, in another recent study that was conducted among patients with first-line standard quadruple therapy (clarithromycin&#x02013;amoxicillin&#x02013;bismuth&#x02013;omeprazole) failure, it was revealed that gemifloxacin-containing quadruple therapy provided high <italic>H. pylori</italic> eradication rate.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> It seems that the first-line status of the patients affects the treatment results.
</p><p>
A limitation of our study was the lack of regional estimates of eradication rates with regard to antibiotic resistance. As these studies require personal-based evaluations and the drug resistance rate should be determined in each comparative study the expression of the adverse results obtained in this study highlights the consideration of the other factors such as gastric microbiota in the study population.<sup><xref rid="R30" ref-type="bibr">30</xref></sup>
</p><p>
Furthermore, the results of this study may not be applicable to patients who failed other treatments. Although the incidence of drug side-effects was similar between the two antibiotics, our findings showed that gemifloxacin was not a good alternative for clarithromycin. Because of the overt usage of macrolids in Iran, the drug resistance has been increased, so this study recommended reducing the over-prescription of such antibiotics by physicians. Also, other fluoroquinolone-containing regimens such as levofloxacine or ofloxacin would be good alternatives for clarithromycin, but it should be noted that in order to avoid a further rapid increase in <italic>H. pylori</italic> resistance to such alternative antibiotics, the usage of quinolones-based regimens should be confined to rescue therapy only.
</p></sec></body><back><ack><p>
We would like to thank all members of Gastrointestinal &#x00026; Liver Diseases Research Center (GLDRC). Also, we would like to thank all the hospital staff that assisted us in this study.
</p></ack><fn-group><fn id="n1" fn-type="COI-statement"><p>
The authors declare no conflict of interest related to this work.
</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Goh</surname><given-names>K-L</given-names></name><name><surname>Chan</surname><given-names>W-K</given-names></name><name><surname>Shiota</surname><given-names>S</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><article-title>Epidemiology of Helicobacter pylori Infection and Public Health Implications</article-title><source>Helicobacter</source><year>2011</year><volume>16</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00874.x</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>Franceschi</surname><given-names>F</given-names></name><name><surname>Zuccala</surname><given-names>G</given-names></name><name><surname>Roccarina</surname><given-names>D</given-names></name><name><surname>Gasbarrini</surname><given-names>A</given-names></name><article-title>Clinical effects of Helicobacter pylori outside the stomach</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2014</year><volume>11</volume><fpage>234</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2013.243</pub-id><pub-id pub-id-type="pmid">24345888</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Mansour-Ghanaei</surname><given-names>F</given-names></name><name><surname>Joukar</surname><given-names>F</given-names></name><name><surname>Naghipour</surname><given-names>MR</given-names></name><name><surname>Forouhari</surname><given-names>A</given-names></name><name><surname>Seyed Saadat</surname><given-names>SM</given-names></name><article-title>Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>661</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i2.661</pub-id><pub-id pub-id-type="pmid">25593496</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Ford</surname><given-names>AC</given-names></name><name><surname>Delaney</surname><given-names>BC</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name><article-title>Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients</article-title><source>Cochrane Database Syst Rev</source><year>2016</year><volume>2</volume><fpage>CD003840</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD003840.pub2</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><name><surname>Cristofari</surname><given-names>F</given-names></name><name><surname>Andriani</surname><given-names>A</given-names></name><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Lerardi</surname><given-names>E</given-names></name><etal/><article-title>Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><volume>8</volume><fpage>105</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2009.07.017</pub-id><pub-id pub-id-type="pmid">19631287</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Ma</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>KF</given-names></name><etal/><article-title>Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality</article-title><source>J Natl Cancer Inst</source><year>2012</year><volume>104</volume><fpage>488</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/jnci/djs003</pub-id><pub-id pub-id-type="pmid">22271764</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>CA</given-names></name><name><surname>Atherton</surname><given-names>J</given-names></name><name><surname>Axon</surname><given-names>AT</given-names></name><name><surname>Bazzoli</surname><given-names>F</given-names></name><etal/><article-title>Management of Helicobacter pylori infection&#x02014;the Maastricht IV/Florence Consensus Report</article-title><source>Gut</source><year>2012</year><volume>61</volume><fpage>646</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2012-302084</pub-id><pub-id pub-id-type="pmid">22491499</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Fischbach</surname><given-names>L</given-names></name><article-title>Helicobacter pylori treatment in the era of increasing antibiotic resistance</article-title><source>Gut</source><year>2010</year><volume>59</volume><fpage>1143</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1136/gut.2009.192757</pub-id><pub-id pub-id-type="pmid">20525969</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Shiotani</surname><given-names>A</given-names></name><article-title>Newer concepts regarding resistance in the treatment Helicobacter pylori infections</article-title><source>Nat Clin Pract Gasteroentrol Hepatol</source><year>2008</year><volume>5</volume><fpage>321</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/ncpgasthep1138</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Camargo</surname><given-names>MC</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Riquelme</surname><given-names>A</given-names></name><name><surname>Otero</surname><given-names>W</given-names></name><name><surname>Carmago</surname><given-names>CA</given-names></name><name><surname>Hernandez-Garcia</surname><given-names>T</given-names></name><etal/><article-title>The problem of Helicobacter pylori resistance to antibiotics: a systemic review</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>485</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.24</pub-id><pub-id pub-id-type="pmid">24589670</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Farshad</surname><given-names>S</given-names></name><name><surname>Alborzi</surname><given-names>A</given-names></name><name><surname>Japoni</surname><given-names>A</given-names></name><name><surname>Ranjbar</surname><given-names>R</given-names></name><name><surname>Hosseini ASI</surname><given-names>K</given-names></name><etal/><article-title>Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>5746</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i45.5746</pub-id><pub-id pub-id-type="pmid">21128326</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Abadi</surname><given-names>AT</given-names></name><name><surname>Taghavi</surname><given-names>T</given-names></name><name><surname>Mobarez</surname><given-names>AM</given-names></name><name><surname>Carpenter</surname><given-names>BM</given-names></name><article-title>Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran</article-title><source>J Microbio</source><year>2011</year><volume>49</volume><fpage>987</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s12275-011-1170-6</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Ashtari</surname><given-names>S</given-names></name><name><surname>Pourhoseingholi</surname><given-names>MA</given-names></name><name><surname>Molaei</surname><given-names>M</given-names></name><name><surname>Taslimi</surname><given-names>H</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name><article-title>The prevalence of Helicobacter pylori is decreasing in Iranian patients</article-title><source>Gasteroentrol Hepatol Bed Bench</source><year>2015</year><volume>8</volume><issue>Suppl 1</issue><fpage>23</fpage><lpage>9</lpage></element-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="other">
Mark C. Henderson, Lawrence M. Tierney Jr., Gerald W. Smetana. The Patient History: An Evidence-Based Approach to Differential Diagnosis. Chapter 34. Dyspepsia .McGraw-Hill; 2012.
</mixed-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Chuah</surname><given-names>SK</given-names></name><name><surname>Tsay</surname><given-names>FW</given-names></name><name><surname>Hsu</surname><given-names>PI</given-names></name><name><surname>Wu</surname><given-names>DC</given-names></name><article-title>A new look at anti-Helicobacter pylori therapy</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><fpage>3971</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i35.3971</pub-id><pub-id pub-id-type="pmid">22046084</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Chuah</surname><given-names>SK</given-names></name><name><surname>Hsu</surname><given-names>PI</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Chiu</surname><given-names>YC</given-names></name><name><surname>Wu</surname><given-names>KL</given-names></name><name><surname>Chou</surname><given-names>YP</given-names></name><etal/><article-title>Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori</article-title><source>Helicobacter</source><year>2012</year><volume>17</volume><fpage>216</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00937.x</pub-id><pub-id pub-id-type="pmid">22515360</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Chuah</surname><given-names>SK</given-names></name><name><surname>Tai</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Liang</surname><given-names>CM</given-names></name><name><surname>Hu</surname><given-names>TH</given-names></name><article-title>Quinolone containing therapies in the eradication of Helicobacter pylori</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>151543</fpage><pub-id pub-id-type="doi">10.1155/2014/151543</pub-id><pub-id pub-id-type="pmid">25243116</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Fakheri</surname><given-names>H</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Merat</surname><given-names>S</given-names></name><name><surname>Khatibian</surname><given-names>M</given-names></name><name><surname>Fazel</surname><given-names>A</given-names></name><name><surname>Alizadeh</surname><given-names>BZ</given-names></name><name><surname>Massarrat</surname><given-names>S</given-names></name><article-title>Clarithromycin vs furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>411</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.00931.x</pub-id><pub-id pub-id-type="pmid">11207517</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Le</surname><given-names>TP</given-names></name><name><surname>Xiang</surname><given-names>YQ</given-names></name><article-title>Gemifloxacin Drugs Todays</article-title><source>(Barc)</source><year>2001</year><volume>37</volume><fpage>401</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1358/dot.2001.37.6.627959</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Amitabh</surname><given-names>V</given-names></name><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Rizvi</surname><given-names>YS</given-names></name><name><surname>Mishra</surname><given-names>P</given-names></name><article-title>Efficacy and safety of oral Gemifloxacin for the empirical treatment of Pneumonia</article-title><source>Lung India</source><year>2012</year><volume>29</volume><fpage>248</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.4103/0970-2113.99109</pub-id><pub-id pub-id-type="pmid">22919164</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Sethi</surname><given-names>S</given-names></name><name><surname>Fogarty</surname><given-names>C</given-names></name><name><surname>Fulambarker</surname><given-names>A</given-names></name><article-title>A randomized, double-blined study comparing 5 days oral Gemifloxacin with 7 days oral Levofloxacin in patients with acute exacerbations of chronic bronchitis</article-title><source>Respir Med</source><year>2008</year><volume>98</volume><fpage>697</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2004.03.028</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Schentag</surname><given-names>JJ</given-names></name><name><surname>Ball</surname><given-names>P</given-names></name><name><surname>Mandell</surname><given-names>L</given-names></name><article-title>A comparison of Gemifloxacin and Clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes</article-title><source>Clin Ther</source><year>2004</year><volume>24</volume><fpage>639</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/S0149-2918(02)85139-6</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Lec</surname><given-names>PI</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name><article-title>In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2010</year><volume>29</volume><fpage>1369</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1007/s10096-010-1009-9</pub-id><pub-id pub-id-type="pmid">20658256</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Minakari</surname><given-names>M</given-names></name><name><surname>Davarpanah Jazi</surname><given-names>AH</given-names></name><name><surname>Shavakhi</surname><given-names>A</given-names></name><name><surname>Moghareabed</surname><given-names>N</given-names></name><name><surname>Fatahi</surname><given-names>F</given-names></name><article-title>A randomized controlled trial: Efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection</article-title><source>Helicobacter</source><year>2010</year><volume>15</volume><fpage>154</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2009.00739.x</pub-id><pub-id pub-id-type="pmid">20402818</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Nasa</surname><given-names>M</given-names></name><name><surname>Choksey</surname><given-names>A</given-names></name><name><surname>Phadke</surname><given-names>A</given-names></name><name><surname>Sawant</surname><given-names>P</given-names></name><article-title>Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized study</article-title><source>Indian J Gastroenterol</source><year>2013</year><volume>32</volume><fpage>392</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s12664-013-0357-7</pub-id><pub-id pub-id-type="pmid">24158898</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Chang</surname><given-names>WL</given-names></name><name><surname>Kao</surname><given-names>CY</given-names></name><name><surname>Huang</surname><given-names>AH</given-names></name><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><name><surname>Cheng</surname><given-names>HC</given-names></name><etal/><article-title>Gemifloxacin can partially overcome quinolone resistance of Hpylori with gyrA mutation in Taiwan</article-title><source>Helicobacter</source><year>2012</year><volume>17</volume><fpage>210</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00935.x</pub-id><pub-id pub-id-type="pmid">22515359</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Masoodi</surname><given-names>M</given-names></name><name><surname>Talebi-Taher</surname><given-names>M</given-names></name><name><surname>Tabatabaie</surname><given-names>KH</given-names></name><name><surname>Khaleghi</surname><given-names>S</given-names></name><name><surname>Faghihi</surname><given-names>AH</given-names></name><name><surname>Agah</surname><given-names>SH</given-names></name><etal/><article-title>Clarithromycin vs Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial</article-title><source>Middle East J Dig Dis</source><year>2015</year><volume>7</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">26106468</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Minehart</surname><given-names>HW</given-names></name><name><surname>Chalker</surname><given-names>AF</given-names></name><article-title>In vitro Activity of Gemifloxacin against Helicobacter pylori</article-title><source>J Antimicrob Chemother</source><year>2001</year><volume>47</volume><fpage>360</fpage><lpage>1</lpage><pub-id pub-id-type="doi">10.1093/jac/47.3.360</pub-id><pub-id pub-id-type="pmid">11222574</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><name><surname>Mahmoudi</surname><given-names>L</given-names></name><name><surname>Farshad</surname><given-names>S</given-names></name><name><surname>Seddigh</surname><given-names>M</given-names></name><name><surname>Mahmoudi</surname><given-names>P</given-names></name><name><surname>Ejtehadi</surname><given-names>F</given-names></name><name><surname>Niknam</surname><given-names>R</given-names></name><article-title>High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><fpage>e4410</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000004410</pub-id><pub-id pub-id-type="pmid">27759625</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><name><surname>Malfertheiner</surname><given-names>P</given-names></name><name><surname>Megraud</surname><given-names>F</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>CA</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Axon</surname><given-names>AT</given-names></name><etal/><article-title>Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>6</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-312288</pub-id><pub-id pub-id-type="pmid">27707777</pub-id></element-citation></ref></ref-list></back></article>